This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis
The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. ... Bristol Myers Squibb has announced interim results from the phase 3 extension trial DAYBREAK,
The FDA has approved Zeposia ( ozanimod) for the treatment of the chronic inflammatory bowel disease based on data from the phase 3 True North study.
In March 2020, the FDA also approved Bristol Myers Squibb’s (BMS) own S1P receptor modulator Zeposia ( ozanimod) for the treatment of adults with relapsing forms of MS.
BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel).
That competition paves the way for new entries, including Novartis’ ofatumumab and Bristol-Myers Squibb’s oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod which is also currently under review with
More from news
Approximately 4 fully matching, plus 24 partially matching documents found.
The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...